Cargando…

Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double‐blind, placebo‐controlled Effisayil™ 1 study

Generalized pustular psoriasis is a potentially life‐threatening neutrophilic skin disease characterized by recurrent flares of widespread erythema and eruption of sterile pustules. In the Effisayil™ 1 study (NCT03782792), 53 patients with a generalized pustular psoriasis flare were treated with pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morita, Akimichi, Tsai, Tsen‐Fang, Yee, Evelyn Yap Wen, Okubo, Yukari, Imafuku, Shinichi, Zheng, Min, Li, Ling, Quaresma, Manuel, Thoma, Christian, Choon, Siew Eng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092680/ https://www.ncbi.nlm.nih.gov/pubmed/36282833 http://dx.doi.org/10.1111/1346-8138.16609

Ejemplares similares

Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis
por: Morita, Akimichi, et al.
Publicado: (2022)

Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare
por: Choon, Siew Eng, et al.
Publicado: (2021)

Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial
por: Tsai, Tsen-Fang, et al.
Publicado: (2023)

Rapid response of spesolimab in biologics – failure patient with generalized pustular psoriasis flare
por: Jiang, Meng, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
por: Choon, Siew Eng, et al.
Publicado: (2023)

Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis
por: Morita, Akimichi, et al.
Publicado: (2021)

Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: Results from the Medical Data Vision claims database
por: Morita, Akimichi, et al.
Publicado: (2021)

Clinical Course and Characteristics of Generalized Pustular Psoriasis
por: Choon, Siew Eng, et al.
Publicado: (2022)

Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180‐week follow‐up results from the phase 3, multicenter IMMspire study
por: Yamanaka, Keiichi, et al.
Publicado: (2022)

Clinical characteristics and health‐care resource utilization in patients with generalized pustular psoriasis using real‐world evidence from the Japanese Medical Data Center database
por: Okubo, Yukari, et al.
Publicado: (2021)

A pustular psoriasis flare treated with calcium supplementation
por: Masson, Laure, et al.
Publicado: (2021)

Clinical Disease Measures in Generalized Pustular Psoriasis
por: Burden, A. David, et al.
Publicado: (2022)

Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis
por: Shao, Shuai, et al.
Publicado: (2022)

Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open‐label phase 3 study
por: Morita, Akimichi, et al.
Publicado: (2018)

Spesolimab: First Approval
por: Blair, Hannah A.
Publicado: (2022)

Understanding Flares in Patients With Generalized Pustular Psoriasis Documented in US Electronic Health Records
por: Zema, Carla L., et al.
Publicado: (2022)

Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results
por: Okubo, Yukari, et al.
Publicado: (2022)

Correction to: Spesolimab: First Approval
por: Blair, Hannah A.
Publicado: (2022)

Tozinameran: Flare-up of generalised pustular psoriasis and systemic capillary leak syndrome: case report
Publicado: (2022)

Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study
por: Bellinato, Francesco, et al.
Publicado: (2023)

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
por: Igarashi, Atsuyuki, et al.
Publicado: (2021)

A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report
por: Onsun, Nahide, et al.
Publicado: (2021)

Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
por: Imafuku, Shinichi, et al.
Publicado: (2021)

Spesolimab use in treatment of pyoderma gangrenosum
por: Guénin, Sophie H., et al.
Publicado: (2023)

Clinical and genetic differences between pustular psoriasis subtypes
por: Twelves, Sophie, et al.
Publicado: (2019)

Telmisartan aggravates pustular psoriasis
por: Keerthi, Subramaniam, et al.
Publicado: (2015)

Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018)

Pathophysiology of Generalized Pustular Psoriasis
por: Marrakchi, Slaheddine, et al.
Publicado: (2022)

Diagnosis of Generalized Pustular Psoriasis
por: Fujita, Hideki, et al.
Publicado: (2022)

Remission einer therapierefraktären generalisierten pustulösen Psoriasis unter dem Interleukin-36-Rezeptor-Inhibitor Spesolimab
por: Müller, Valentina Laura, et al.
Publicado: (2023)

Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists
por: Strober, Bruce, et al.
Publicado: (2021)

Successful use of secukinumab in pustular psoriasis
por: Yeung, Jensen, et al.
Publicado: (2016)

Pustular psoriasis of pregnancy: current perspectives
por: Trivedi, Megha K, et al.
Publicado: (2018)

Generalized pustular psoriasis (von Zumbusch)()
por: Romiti, Ricardo, et al.
Publicado: (2022)

Pustular Psoriasis: From Pathophysiology to Treatment
por: Genovese, Giovanni, et al.
Publicado: (2021)

Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis
por: Okubo, Yukari, et al.
Publicado: (2021)

Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP)
por: Burden, A. David, et al.
Publicado: (2022)

Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
por: Burden, A. David, et al.
Publicado: (2023)

Chronic annular pustular psoriasis resembling subcorneal pustular dermatosis: A case report
por: Khosravi-Hafshejani, Touraj, et al.
Publicado: (2019)

Myeloperoxidase Modulates Inflammation in Generalized Pustular Psoriasis and Additional Rare Pustular Skin Diseases
por: Haskamp, Stefan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kt0vm6fthqckl7m0ns12kv5hrb